We are currently not shipping Ilaris.
Information about Ilaris (Canakinumab)
Ilaris (Canakinumab) is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory cytokine involved in various autoimmune diseases. It is used to reduce inflammation and prevent attacks in certain conditions related to systemic autoinflammatory syndromes.
Product Highlights
- A hereditary inflammatory disorder characterized by recurrent fevers and painful abdominal episodes.
- A group of rare genetic disorders that lead to recurrent episodes of fever, rash, and joint pain due to uncontrolled inflammation.
- A form of arthritis in children that causes persistent joint inflammation, fever, and rash.
- Used in specific cases to manage severe gout flares by reducing inflammation.
Key Ingredient
Key Benefits
- Effectively reduces inflammation associated with autoimmune conditions.
- Reduces frequency and severity of disease flare-ups, enhancing daily living.
- May provide prolonged relief with less frequent dosing compared to some other treatments.
Direction of Use
- Typically administered as a subcutaneous injection, with dosing frequency depending on the condition (e.g., monthly or bi-monthly).
- Patients should be regularly assessed for their response to therapy and any potential side effects.
Safety Concerns
- Common side effects include injection site reactions, headache, and respiratory infections.
- Increased risk of serious infections due to immunosuppression and potential risk of malignancies.
- Regular check-ups are necessary to monitor for infections and overall health.
Avoid Ilaris (Canakinumab) If
- Patients with active infections should not use this medication.
- Known hypersensitivity to Canakinumab or any of its components.
- Conditions that severely compromise immune function.
- Should be avoided unless the potential benefits outweigh risks.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
